GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Realcan Pharmaceutical Group Co Ltd (SZSE:002589) » Definitions » Change In Receivables

Realcan Pharmaceutical Group Co (SZSE:002589) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Realcan Pharmaceutical Group Co Change In Receivables?

Realcan Pharmaceutical Group Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Realcan Pharmaceutical Group Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Realcan Pharmaceutical Group Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥1,122 Mil. It means Realcan Pharmaceutical Group Co's Accounts Receivable declined by ¥1,122 Mil from Dec. 2022 to Dec. 2023 .

Realcan Pharmaceutical Group Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥3,951 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Realcan Pharmaceutical Group Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 178.58.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Realcan Pharmaceutical Group Co's liquidation value for the three months ended in Mar. 2024 was ¥-2,429 Mil.


Realcan Pharmaceutical Group Co Change In Receivables Historical Data

The historical data trend for Realcan Pharmaceutical Group Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Realcan Pharmaceutical Group Co Change In Receivables Chart

Realcan Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -979.80 -198.13 -197.21 -6,339.98 1,121.89

Realcan Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Realcan Pharmaceutical Group Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Realcan Pharmaceutical Group Co  (SZSE:002589) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Realcan Pharmaceutical Group Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=3950.733/2018.759*91
=178.58

2. In Ben Graham's calculation of liquidation value, Realcan Pharmaceutical Group Co's accounts receivable are only considered to be worth 75% of book value:

Realcan Pharmaceutical Group Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=4022.756-9903.392+0.75 * 3950.733+0.5 * 978.041
=-2,429

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Realcan Pharmaceutical Group Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Realcan Pharmaceutical Group Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Realcan Pharmaceutical Group Co (SZSE:002589) Business Description

Traded in Other Exchanges
N/A
Address
No. 326, Airport Road, Zhifu District, Shandong Province, Yantai, CHN, 264004
Realcan Pharmaceutical Group Co Ltd is a Chinese company engaged in direct pharmaceuticals distribution services. The company's main business is divided into the Drug, vaccine, medical device circulation service; Medical industry third-party logistics; Medical information service; Medical logistics service; Chinese medicine plate; Hospital management sector; Medical industry research and development production sector; and Medical industry financial sector.
Executives
Zhang Ren Hua Directors, executives
Han Xu Director
Zhou Yun Directors, Directors, and Executives
Wu Di Executives
Su Li Chen Executives
Wu Li Yan Director
Tao Chun Fang Supervisors
Han Song Executives

Realcan Pharmaceutical Group Co (SZSE:002589) Headlines

No Headlines